Re: Rano Matta, Refik Saskin, Sarah Neu, et al. Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.001
-
Published:2023-10
Issue:
Volume:
Page:
-
ISSN:2405-4569
-
Container-title:European Urology Focus
-
language:en
-
Short-container-title:European Urology Focus
Author:
Rosato Eleonora,
Lombardo RiccardoORCID,
Li Marzi Vincenzo,
Finazzi Agrò Enrico,
De Nunzio Cosimo,
Albisinni Simone
Reference5 articles.
1. Matta R, Saskin R, Neu S, et al. Predicting mirabegron treatment response in patients with overactive bladder: a post hoc analysis of data from clinical trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.001.
2. Treatment of non-neurogenic lower urinary tract symptoms—a review of key publications from 2018 onward;Abreu-Mendes;Eur Urol Focus,2021
3. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis;Su;Medicine,2020
4. Mjaess G, Karam A, Roumeguère T, et al. Urinary microbiota and prostatic diseases: the key for the lock? A systematic review. Prostate Cancer Prostat Dis. In press. https://doi.org/10.1038/s41391-022-00602-w.
5. The urothelium, the urinary microbioma and men LUTS: a systematic review;Lombardo;Minerva Urol Nefrol,2020